Accumulation of Immunity in Heavy-Tailed Sexual Contact Networks Shapes Mpox Outbreak Sizes.

Authors:
Murayama H; Pearson CAB; Abbott S; Miura F; Jung SM and 3 more

Journal:
J Infect Dis

Publication Year: 2024

DOI:
10.1093/infdis/jiad254

PMCID:
PMC10786257

PMID:
37402631

Journal Information

Full Title: J Infect Dis

Abbreviation: J Infect Dis

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Communicable Diseases

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Evidence found in paper:

"the analysis codes are available from a github repository: https://github com/hiroaki-murayama/mpx_depletion_susceptibles ."

Evidence found in paper:

"Potential conflicts of interest. A. E. received a research grant from Taisho Pharmaceutical Co, Ltd for research outside this study. F. M. received a research grant from AdvanSentinel Inc for research outside this study. All other authors report no potential conflicts.: All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed."

Evidence found in paper:

"Financial support. A. E. is supported by Japan Society for the Promotion of Science (JSPS) Overseas Research Fellowships. A. E. and F. M. are supported by the JSPS Grants-in-Aid KAKENHI (to A. E., 22K17329; to F. M., 20J00793). A. E. and H. M. are supported by the foundation for the Fusion of Science and Technology (to A. E.) and the Japan Science and Technology Agency Precursory Research for Embryonic Science and Technology (to A. E., JPMJPR22R3). S. F. and S. A. are supported by Wellcome Trust (to S. F., 210758/Z/18/Z). C. A. B. P. is supported by the Innovative Medicines Initiative 2 joint undertaking under grant agreement EBOVAC3 (800176); this joint undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). S. J. is supported by the Centers for Disease Control and Prevention SHEPheRD (200-2016-91781). E. F. is supported by the Medical Research Council, United Kingdom Research and Innovation (MR/S020462/1). Financial support ."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025